Lupin stock initiated at Equalweight by Morgan Stanley amid turnaround

Morgan Stanley initiated coverage on Lupin (NSE:LUPN) with an Equalweight rating and an INR2,096.00 price target, citing the company's turnaround efforts, including recent U.S. product launches and cost controls expected to improve FY25 margins. However, the firm flagged significant headwinds such as structural U.S. market challenges, competitive pressures, potential FY27 margin contraction from exclusivity expiry, and ongoing litigation, which pose risks to long-term growth and earnings visibility, despite Lupin's current valuation of 23x FY27 estimated P/E being below its 10-year average.

Analysis

Morgan Stanley has initiated coverage on Lupin with an Equalweight rating and an INR 2,096.00 price target, reflecting a balanced view of the company's prospects. The firm acknowledges positive momentum from an ongoing turnaround, driven by recent U.S. product launches like generic Myrbetriq and Jynarque, alongside cost-control initiatives. These factors are expected to enhance margins in fiscal year 2025 and sustain earnings growth into fiscal 2026. However, this outlook is tempered by significant headwinds, including structural challenges and persistent competition within the U.S. market. Critically, Morgan Stanley projects a 100 basis point margin contraction in fiscal 2027 as these product exclusivities expire. A key overhang is the ongoing litigation with Astellas Pharma regarding the at-risk launch of Mirabegron, which poses a material risk to earnings visibility. While Lupin's valuation at 23x estimated FY27 P/E trades below its 10-year historical average of 25x, this modest discount appears to factor in the identified long-term pressures and legal uncertainties.

Key Decisions for Investors

• Investors should weigh the near-term earnings uplift from recent product launches against the significant long-term risks of margin contraction post-FY26 and structural U.S. market pressures, aligning with the neutral 'Equalweight' stance.
• Closely monitor developments in the Astellas Pharma litigation, as a negative outcome could materially impact future earnings and invalidate the current investment thesis.
• Focus on margin performance as a key indicator; while improvement is expected in FY25, the forecasted margin decline in FY27 is a critical datapoint to watch for signs of deteriorating long-term profitability.
• Recognize that the current valuation, while at a slight discount to its historical average, likely reflects the combination of near-term tailwinds and significant, clearly articulated long-term risks.